On the public citation graph

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

https://doi.org/10.1016/j.jval.2013.10.008
0 signed · 83 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2009.1409openalex-snapshot
Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions
inferredcites →https://doi.org/10.1007/s10198-008-0114-5openalex-snapshot
Pricing and reimbursement of pharmaceuticals in Italy
inferredcites →https://doi.org/10.1007/s11096-007-9141-zopenalex-snapshot
Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden
inferredcites →https://doi.org/10.1016/j.healthpol.2005.08.006openalex-snapshot
The Common Drug Review: A NICE start for Canada?
inferredcites →https://doi.org/10.1111/j.1524-4733.2009.00620.xopenalex-snapshot
Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan
inferredcites →https://doi.org/10.1111/j.1524-4733.2009.00621.xopenalex-snapshot
Evidence-Based Decision-Making on Medical Technologies in China, Japan, and Singapore
inferredcites →https://doi.org/10.1377/hlthaff.27.1.179openalex-snapshot
Economic Evaluation And Pharmaceutical Reimbursement Reform In South Korea’s National Health Insurance
inferredcites →https://doi.org/10.1503/cmaj.051622openalex-snapshot
On bias and transparency in the development of influential recommendations
inferredcites →https://doi.org/10.1787/135870415741openalex-snapshot
Pharmaceutical Pricing and Reimbursement Policies in Sweden
inferredcites →https://doi.org/10.1787/136157357151openalex-snapshot
Pharmaceutical Pricing and Reimbursement Policies in Switzerland
inferredcites →https://doi.org/10.1787/346071162287openalex-snapshot
Pharmaceutical Pricing and Reimbursement Policies in Canada
inferredcites →https://doi.org/10.2139/ssrn.1156608openalex-snapshot
The Economics of Pharmaceutical Pricing and Physician Prescribing in Japan
inferredcites →https://doi.org/10.2139/ssrn.1329308openalex-snapshot
Pharmaceutical Pricing and Reimbursement Policies in Canada
inferredcites →https://doi.org/10.2139/ssrn.1329310openalex-snapshot
Pharmaceutical Pricing and Reimbursement Policies in Sweden
inferredcites →https://doi.org/10.2165/00019053-200826090-00004openalex-snapshot
The NICE Cost-Effectiveness Threshold
inferredcites →https://doi.org/10.3233/ppl-2009-0222openalex-snapshot
Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain
inferredcites →https://doi.org/10.5694/j.1326-5377.2008.tb01500.xopenalex-snapshot
Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4650638openalex-extracted
New Compound Real Option Pricing Method with Lévy Processes for the Quality-by-Design Pharmaceutical R&D
inferred← citeshttps://doi.org/10.1001/jamainternmed.2015.7230openalex-snapshot
Finding the Right Price for Improving Care
inferred← citeshttps://doi.org/10.1002/cpt.2051openalex-snapshot
Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development
inferred← citeshttps://doi.org/10.1002/hec.70095openalex-snapshot
Strategic Delay and Bargaining Over Public Insurance Coverage for Drugs in Australia
inferred← citeshttps://doi.org/10.1002/hpm.2372openalex-snapshot
The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?
inferred← citeshttps://doi.org/10.1002/psp4.12579openalex-snapshot
Combining Model‐Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design
inferred← citeshttps://doi.org/10.1007/s10198-017-0916-4openalex-snapshot
Patient preferences: a Trojan horse for evidence-based medicine?
inferred← citeshttps://doi.org/10.1007/s10198-023-01655-xopenalex-snapshot
AOTMiT reimbursement recommendations compared to other HTA agencies
inferred← citeshttps://doi.org/10.1007/s40258-023-00858-wopenalex-snapshot
Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?
inferred← citeshttps://doi.org/10.1007/s40258-023-00867-9openalex-snapshot
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
inferred← citeshttps://doi.org/10.1007/s40273-018-0610-0openalex-snapshot
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017
inferred← citeshttps://doi.org/10.1007/s40273-024-01450-3openalex-snapshot
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
inferred← citeshttps://doi.org/10.1007/s40274-014-0997-6openalex-snapshot
Examining drug reimbursement decision-making in the OECD
inferred← citeshttps://doi.org/10.1016/j.dentre.2022.100058openalex-snapshot
Patients’ view on non-surgical and surgical periodontal therapy in relation to oral health: A narrative review
inferred← citeshttps://doi.org/10.1016/j.esmoop.2022.100569openalex-snapshot
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
inferred← citeshttps://doi.org/10.1016/j.healthpol.2017.03.010openalex-snapshot
HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey
inferred← citeshttps://doi.org/10.1016/j.healthpol.2018.11.003openalex-snapshot
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries
inferred← citeshttps://doi.org/10.1016/j.healthpol.2019.05.021openalex-snapshot
Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
inferred← citeshttps://doi.org/10.1016/j.healthpol.2020.12.007openalex-snapshot
Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland
inferred← citeshttps://doi.org/10.1016/j.hlpt.2019.09.004openalex-snapshot
The impact of implemented regulations on biosimilars in Slovakia
inferred← citeshttps://doi.org/10.1016/j.jcpo.2015.05.004openalex-snapshot
Why do some countries approve a cancer drug and others don’t?
inferred← citeshttps://doi.org/10.1016/j.jval.2016.08.725openalex-snapshot
Variation in Health Technology Assessment and Reimbursement Processes in Europe
inferred← citeshttps://doi.org/10.1016/j.jval.2017.03.011openalex-snapshot
Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries
inferred← citeshttps://doi.org/10.1016/j.jval.2017.04.002openalex-snapshot
Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia
inferred← citeshttps://doi.org/10.1016/j.jval.2019.10.012openalex-snapshot
Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts
inferred← citeshttps://doi.org/10.1016/j.jval.2019.11.001openalex-snapshot
Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis
inferred← citeshttps://doi.org/10.1016/j.jval.2020.01.013openalex-snapshot
Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries
inferred← citeshttps://doi.org/10.1016/j.socscimed.2020.113042openalex-snapshot
Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US
inferred← citeshttps://doi.org/10.1016/j.vhri.2017.07.002openalex-snapshot
Drug Policy in Slovakia
inferred← citeshttps://doi.org/10.1017/s026646231700006xopenalex-snapshot
INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA
inferred← citeshttps://doi.org/10.1017/s0266462317000423openalex-snapshot
HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY
inferred← citeshttps://doi.org/10.1017/s026646232000032xopenalex-snapshot
Disagreement on cancer drug decisions in Europe
inferred← citeshttps://doi.org/10.1017/s0266462324000485openalex-snapshot
Health technology assessment of medicinal products in Greece: a 5-year (2018–2023) review of timelines and productivity
inferred← citeshttps://doi.org/10.1080/13696998.2021.1946326openalex-snapshot
The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best–worst scaling approach
inferred← citeshttps://doi.org/10.1080/14737167.2016.1215917openalex-snapshot
The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations
inferred← citeshttps://doi.org/10.1080/14737167.2017.1262767openalex-snapshot
The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland
inferred← citeshttps://doi.org/10.1080/14737167.2018.1518135openalex-snapshot
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders
inferred← citeshttps://doi.org/10.1080/14737167.2026.2691186openalex-snapshot
Pharmacoeconomics of high-cost therapies: real world challenges
inferred← citeshttps://doi.org/10.1080/23288604.2024.2329082openalex-snapshot
Is it the Right Topic? An Overlooked Stage in the Institutionalization of Health Technology Assessment
inferred← citeshttps://doi.org/10.1093/eurheartj/ehad514openalex-snapshot
Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management
inferred← citeshttps://doi.org/10.1093/oso/9780197512883.003.0005openalex-snapshot
Measuring Drug Value
inferred← citeshttps://doi.org/10.1111/cts.13027openalex-snapshot
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
inferred← citeshttps://doi.org/10.1136/bmjgh-2023-012780openalex-snapshot
Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
inferred← citeshttps://doi.org/10.1161/jaha.125.043610openalex-snapshot
Impact of Heart Failure Guideline Publication on Medicare Drug Coverage Policies: A Quasi‐Experimental Analysis
inferred← citeshttps://doi.org/10.1177/0272989x16653397openalex-snapshot
Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care
inferred← citeshttps://doi.org/10.1177/27550834231177507openalex-snapshot
Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases
inferred← citeshttps://doi.org/10.1186/s12955-019-1195-9openalex-snapshot
Estimating health state utility from activities of daily living in the French National Hospital Discharge Database: a feasibility study with head and neck cancer
inferred← citeshttps://doi.org/10.1186/s12961-015-0028-5openalex-snapshot
From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
inferred← citeshttps://doi.org/10.1186/s40545-023-00529-0openalex-snapshot
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
inferred← citeshttps://doi.org/10.1201/b18285-2openalex-snapshot
Regulation, Reimbursement and Health Technology Assessment
inferred← citeshttps://doi.org/10.1248/bpb.b19-00798openalex-snapshot
Reduction in the Doses of Direct Oral Anticoagulants and Risk of Ischemic Stroke Events: A Hospital Survey
inferred← citeshttps://doi.org/10.1371/journal.pone.0244546openalex-snapshot
Understanding the use of patient-reported data by health care insurers: A scoping review
inferred← citeshttps://doi.org/10.17749/2070-4909.2019.12.2.146-154openalex-snapshot
Organizational structure and funding of health technology assessment agencies around the world
inferred← citeshttps://doi.org/10.20381/ruor-4352openalex-snapshot
Consideration for Rare Diseases in the Context of Drug Reimbursement Processes
inferred← citeshttps://doi.org/10.2147/ceor.s67375openalex-snapshot
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia
inferred← citeshttps://doi.org/10.3280/mesa2024-131oa20242openalex-snapshot
Putting a financial accounting and a health economic perspective face to face to inform public health management decision-making
inferred← citeshttps://doi.org/10.3389/fphar.2017.00946openalex-snapshot
Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
inferred← citeshttps://doi.org/10.3389/fphar.2019.00664openalex-snapshot
How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
inferred← citeshttps://doi.org/10.3389/fphar.2020.594644openalex-snapshot
Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
inferred← citeshttps://doi.org/10.3389/fphar.2023.1153680openalex-snapshot
Reimbursement decision-making system in Poland systematically compared to other countries
inferred← citeshttps://doi.org/10.3389/fpubh.2018.00052openalex-snapshot
Systematic Review of Health Economic Evaluation Studies Developed in Brazil from 1980 to 2013
inferred← citeshttps://doi.org/10.3390/curroncol29030156openalex-snapshot
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021
inferred← citeshttps://doi.org/10.3390/ijerph19127281openalex-snapshot
Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model
inferred← citeshttps://doi.org/10.3747/co.v18i1.878openalex-snapshot
E-Manuscript Article Summaries
inferred← citeshttps://doi.org/10.5152/ced.2014.0007openalex-snapshot
Pharmacoeconomic Analysis of Vaccination in Developed Versus Developing Countries
inferred← citeshttps://doi.org/10.7326/m20-1392openalex-snapshot
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.